Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | CFTR | P13569 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA5A | P35218 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8421994 | 0.88 | ALDH1A1 (0.55) | MEN1KMT2ASMN1; SMN2ALDH1A1POLB | |
| SCHEMBL17707780 | 0.84 | ALDH1A1 (0.49) | MEN1KMT2ASMN1; SMN2ALDH1A1POLB | |
| SCHEMBL6551228 | 0.83 | TSHR (0.56) | MEN1KMT2ASMN1; SMN2ALDH1A1POLB | |
| SCHEMBL17707772 | 0.83 | CRHBP (0.46) | MEN1KMT2ASMN1; SMN2ALDH1A1POLB | |
| SCHEMBL17707775 | 0.83 | TSHR (0.53) | MEN1KMT2ASMN1; SMN2ALDH1A1POLB | |
| SCHEMBL16957915 | 0.82 | ALDH1A1 (0.50) | MEN1KMT2ASMN1; SMN2ALDH1A1POLB | |
| SCHEMBL7369896 | 0.82 | TSHR (0.54) | MEN1KMT2ASMN1; SMN2ALDH1A1POLB | |
| SCHEMBL2521491 | 0.82 | HPGD (0.52) | MEN1KMT2ASMN1; SMN2ALDH1A1POLB | |
| SCHEMBL27746873 | 0.82 | ALDH1A1 (0.61) | MEN1KMT2ASMN1; SMN2ALDH1A1POLB | |
| SCHEMBL1032670 | 0.82 | ALDH1A1 (0.68) | MEN1KMT2ASMN1; SMN2ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109071411-B | Method for producing nitrobenzene compound | 组合化学工业株式会社 | 2021-08-27 | — | — | CN | disclosed |
| EP-3456705-B1 | METHOD FOR PRODUCING NITROBENZENE COMPOUND | KUMIAI CHEMICAL INDUSTRY CO (JP) | 2020-12-16 | — | — | EP | disclosed |
| EP-3456705-A1 | METHOD FOR PRODUCING NITROBENZENE COMPOUND | Kumiai Chemical Industry Co., Ltd. (JP) | 2019-03-20 | — | — | EP | disclosed |
| EP-3015451-B1 | METHOD FOR PRODUCING NITROBENZENE COMPOUND | KUMIAI CHEMICAL INDUSTRY CO (JP) | 2018-01-17 | — | — | EP | disclosed |
| CN-104114557-B | 8-substituted 2-amino- [1,2,4] triazolo [1,5-a ] pyrazines as SYK tyrosine kinase inhibitors and GCN2 serine kinase inhibitors | 默克专利股份公司 | 2017-10-24 | — | — | CN | disclosed |
| CN-103748094-B | Tricyclic sulfonamide compounds and methods of making and using the same | 扎夫根股份有限公司 | 2016-06-29 | — | — | CN | disclosed |
| EP-3015451-A1 | METHOD FOR MANUFACTURING NITROBENZENE COMPOUND | Ihara Chemical Industry Co., Ltd. (JP) | 2016-05-04 | — | — | EP | disclosed |
| EP-2443092-B1 | BICYCLIC AND TRICYCLIC COMPOUNDS AS KAT II INHIBITORS | PFIZER (US) | 2015-04-08 | — | — | EP | disclosed |
| CN-104159901-A | Triazolopyrazine derivatives | MERCK PATENT GMBH | 2014-11-19 | — | — | CN | disclosed |
| CN-102574814-A | Process for preparation of pyrimidinylacetonitrile derivatives and intermediates for synthesis thereof | IHARA CHEMICAL IND CO | 2012-07-11 | — | — | CN | disclosed |
| US-8183238-B2 | Bicyclic and tricyclic compounds as KAT II inhibitors | PFIZER INC. (US) | 2012-05-22 | — | — | US | disclosed |
| EP-2443092-A1 | BICYCLIC AND TRICYCLIC COMPOUNDS AS KAT II INHIBITORS | Pfizer Inc. (US) | 2012-04-25 | — | — | EP | disclosed |
| US-20100324043-A1 | Bicyclic And Tricyclic Compounds As KAT II Inhibitors | PFIZER INC | 2010-12-23 | — | — | US | disclosed |
| WO-2010146488-A1 | BICYCLIC AND TRICYCLIC COMPOUNDS AS KAT II INHIBITORS | PFIZER INC. (US) | 2010-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324043-A1 | Bicyclic And Tricyclic Compounds As KAT II Inhibitors | KAT2A, KAT2B, KAT6B | MEN1 4474/4885KMT2A 48/4885SMN1; SMN2 3284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.